Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Company Overview

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Key Stats

• Today's Range: $0.39 to $0.48
• 50-Day Range: $0.23 to $0.70
• 52-Week Range: $0.22 to $1.30
• Volume: 1.95 million shs
• Average Volume: 4.46 million shs
• Market Capitalization: $4.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Strong Buy

Adial Pharmaceuticals Stock Analysis - MarketRank™

Adial Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Adial Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adial Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adial Pharmaceuticals is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adial Pharmaceuticals is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adial Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.29% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently decreased by 63.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adial Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Adial Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.29% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently decreased by 63.46%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Adial Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 10 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

18 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.26% of the stock of Adial Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 16.41% of the stock of Adial Pharmaceuticals is held by institutions.

ADIL Stock Analysis - Frequently Asked Questions

How have ADIL shares performed this year?

Adial Pharmaceuticals' stock was trading at $1.01 at the beginning of 2025. Since then, ADIL stock has decreased by 54.9% and is now trading at $0.4551.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.16.

When did Adial Pharmaceuticals' stock split?

Shares of Adial Pharmaceuticals reverse split before market open on Monday, August 7th 2023.The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Adial Pharmaceuticals IPO?

Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADIL
• CIK: 1513525
• Web: www.adialpharma.com
• Phone: (434) 422-9800
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adial Pharmaceuticals: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,657.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -218.88%
• Return on Assets: -177.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.99
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 10,435,000
• Free Float: 9,990,000
• Market Cap: $4.75 million
• Optionable: No Data
• Beta: 1.02